Citigroup Inc Hutchmed (China) LTD Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Citigroup Inc holds 851 shares of HCM stock, worth $15,318. This represents 0.0% of its overall portfolio holdings.

Number of Shares

851

Previous 308 176.3%

Holding current value

$15,318

Previous $5,000 180.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$16.36 - $21.78 $8,883 - $11,826	543 Added 176.3%	851 $14,000
Q1 2024 May 10, 2024	SELL	$12.08 - $18.56 $5,399 - $8,296	-447 Reduced 59.21%	308 $5,000
Q4 2023 Feb 09, 2024	BUY	$16.25 - $20.23 $2,502 - $3,115	154 Added 25.62%	755 $13,000
Q3 2023 Nov 09, 2023	SELL	$11.85 - $16.95 $17,917 - $25,628	-1,512 Reduced 71.56%	601 $10,000
Q2 2023 Aug 10, 2023	SELL	$10.78 - $17.73 $167,391 - $275,311	-15,528 Reduced 88.02%	2,113 $25,000
Q1 2023 May 11, 2023	BUY	$13.02 - $19.87 $194,362 - $296,619	14,928 Added 550.24%	17,641 $229,000
Q4 2022 Feb 09, 2023	SELL	$7.65 - $15.51 $103,382 - $209,602	-13,514 Reduced 83.28%	2,713 $40,000
Q3 2022 Nov 10, 2022	SELL	$8.63 - $15.52 $115,642 - $207,968	-13,400 Reduced 45.23%	16,227 $143,000
Q2 2022 Aug 10, 2022	SELL	$8.59 - $20.77 $8,315 - $20,105	-968 Reduced 3.16%	29,627 $375,000
Q1 2022 May 12, 2022	SELL	$15.52 - $35.65 $72,043 - $165,487	-4,642 Reduced 13.17%	30,595 $579,000
Q4 2021 Feb 10, 2022	BUY	$28.89 - $35.33 $45,212 - $55,291	1,565 Added 4.65%	35,237 $1.24 Million
Q3 2021 Nov 10, 2021	BUY	$35.66 - $42.94 $1.2 Million - $1.45 Million	33,672 New	33,672 $1.23 Million

Others Institutions Holding HCM

# of Institutions

Shares Held

8.25M

Call Options Held

3.8K

Put Options Held

2.4K

View Full List

About HUTCHMED (China) Ltd

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

More about HCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account